JP2016514091A - トランスサイレチン抗体およびその使用 - Google Patents

トランスサイレチン抗体およびその使用 Download PDF

Info

Publication number
JP2016514091A
JP2016514091A JP2015557148A JP2015557148A JP2016514091A JP 2016514091 A JP2016514091 A JP 2016514091A JP 2015557148 A JP2015557148 A JP 2015557148A JP 2015557148 A JP2015557148 A JP 2015557148A JP 2016514091 A JP2016514091 A JP 2016514091A
Authority
JP
Japan
Prior art keywords
ttr
mutation
antibody
subject
native
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015557148A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016514091A5 (https=
Inventor
シン ジャン，
シン ジャン，
ジェフリー ダブリュー． ケリー，
ジェフリー ダブリュー． ケリー，
ジャスティン チャプマン，
ジャスティン チャプマン，
Original Assignee
ミスフォールディング ダイアグノスティクス， インコーポレイテッド
ミスフォールディング ダイアグノスティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ミスフォールディング ダイアグノスティクス， インコーポレイテッド, ミスフォールディング ダイアグノスティクス， インコーポレイテッド filed Critical ミスフォールディング ダイアグノスティクス， インコーポレイテッド
Publication of JP2016514091A publication Critical patent/JP2016514091A/ja
Publication of JP2016514091A5 publication Critical patent/JP2016514091A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015557148A 2013-02-08 2014-02-07 トランスサイレチン抗体およびその使用 Pending JP2016514091A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361762750P 2013-02-08 2013-02-08
US61/762,750 2013-02-08
US201361863818P 2013-08-08 2013-08-08
US61/863,818 2013-08-08
PCT/US2014/015421 WO2014124334A2 (en) 2013-02-08 2014-02-07 Transthyretin antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2016514091A true JP2016514091A (ja) 2016-05-19
JP2016514091A5 JP2016514091A5 (https=) 2017-03-02

Family

ID=51300272

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015557148A Pending JP2016514091A (ja) 2013-02-08 2014-02-07 トランスサイレチン抗体およびその使用

Country Status (4)

Country Link
US (2) US9790269B2 (https=)
EP (1) EP2953970A4 (https=)
JP (1) JP2016514091A (https=)
WO (1) WO2014124334A2 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020188700A (ja) * 2019-05-21 2020-11-26 国立大学法人 熊本大学 アミロイドーシス治療薬の新規スクリーニング方法及びアミロイドーシスのための医薬組成物
JP2020536532A (ja) * 2017-10-06 2020-12-17 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
US11873332B2 (en) 2017-11-29 2024-01-16 Novo Nordisk A/S Lyophilized formulation of a monoclonal antibody against transthyretin
US11912759B2 (en) 2015-01-28 2024-02-27 Novo Nordisk A/S Anti-transthyretin antibodies
US12247985B2 (en) 2017-10-06 2025-03-11 Novo Nordisk A/S Methods of detecting transthyretin

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3022225B1 (en) * 2013-07-19 2021-09-29 Board Of Regents Of the University Of Texas System Transthyretin amyloid-selective and polyreactive catabodies
US10344080B2 (en) 2013-12-20 2019-07-09 Neurimmune Holding Ag Antibody-based therapy of transthyretin (TTR) amyloidosis and human-derived antibodies therefor
EP3101131B1 (en) * 2014-01-29 2020-08-19 KM Biologics Co., Ltd. Anti-transthyretin humanized antibody
EP3981874A1 (en) 2014-01-29 2022-04-13 KM Biologics Co., Ltd. Anti-transthyretin human antibody
TWI786505B (zh) * 2015-01-28 2022-12-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
TWI769570B (zh) * 2015-01-28 2022-07-01 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
TWI718121B (zh) * 2015-01-28 2021-02-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
WO2018007922A2 (en) * 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
JP7017013B2 (ja) * 2016-07-02 2022-02-08 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
WO2018007923A2 (en) * 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
EP3468272B1 (en) * 2016-09-10 2025-12-17 LG Electronics Inc. Method for allocating v2x resource pool to subframe remaining after excluding specific subframe in wireless communication system, and terminal using same
BR112019005378A2 (pt) 2016-09-19 2019-08-27 The Trustees Of The University Of Pennsylvania molécula de ácido nucleico, composição, e, métodos para prevenir ou tratar uma doença e para induzir uma resposta imune
WO2019241497A1 (en) * 2018-06-13 2019-12-19 The Wistar Institute Of Anatomy And Biology Dna antibody constructs for use against zika virus
US20210400932A1 (en) 2018-11-09 2021-12-30 Neurimmune Ag Patient-derived amyloid xenograft non-human animal model
EP3976017A4 (en) * 2019-05-31 2023-06-14 Plex Pharmaceuticals, Inc. PHARMACOLOGICAL SUBSTANCES FOR THE TREATMENT OF PROTEIN AGGREGATION DISEASES OF THE EYE
EP3988122A4 (en) * 2019-12-17 2023-01-18 Yizhou (Shanghai) Biological Medicine Co, Ltd. USE OF TRANSTHYRETIN FOR INTRODUCTION TO THE EYE AND MAKING DROPS
CN215606058U (zh) 2020-06-03 2022-01-25 巴德阿克塞斯系统股份有限公司 配置用于与骨内进入系统一起使用的闭塞器组件
CN114098918B (zh) 2020-08-25 2025-12-12 巴德阿克塞斯系统股份有限公司 成角度的骨内进入系统
EP4203821B1 (en) 2020-09-01 2025-10-29 Bard Access Systems, Inc. Retractable intraosseous access system
CN215839325U (zh) * 2020-09-09 2022-02-18 巴德阿克塞斯系统股份有限公司 用于骨内进入系统的抽吸设备
JP7504304B2 (ja) 2021-01-19 2024-06-21 エリモス・ファーマシューティカルズ・リミテッド・ライアビリティ・カンパニー コロナウイルス抗ウイルス剤としてのテラメプロコールおよびノルジヒドログアイアレチン酸（ｎｄｇａ）誘導体
CN217960227U (zh) 2021-02-08 2022-12-06 巴德阿克塞斯系统股份有限公司 骨内进入系统
CN117916599A (zh) 2021-09-07 2024-04-19 美国西门子医学诊断股份有限公司 生物标记物组合物及其使用方法
WO2023099788A1 (en) 2021-12-03 2023-06-08 Neurimmune Ag Novel potency assay for antibody-based drugs and useful means therefor
EP4296279A1 (en) * 2022-06-23 2023-12-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti-transthyretin (ttr) binding proteins and uses thereof
EP4630812A1 (en) 2022-12-05 2025-10-15 Neurimmune AG Cyclic compounds and their use in assays for detecting antibodies
CN116396392B (zh) * 2023-01-17 2023-10-27 珠海重链生物科技有限公司 一种特异性针对异羟基洋地黄毒甙元的抗体及其相关应用
SE2350342A1 (en) * 2023-03-27 2024-09-28 Anders Olofsson Composition for use in prevention and/or treatment of human transthyretin amyloidosis
WO2024240562A1 (en) * 2023-05-19 2024-11-28 Neurimmune Ag Novel immunotherapy for musculoskeletal disorders and conditions
CN121646476A (zh) 2023-06-07 2026-03-10 神经免疫有限公司 用于治疗淀粉样变性的疫苗
WO2025104243A1 (en) 2023-11-15 2025-05-22 Neurimmune Ag Anti-transthyretin antibody, compositions comprising said antibody and methods for treating or preventing transthyretin-mediated amyloidosis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010195710A (ja) * 2009-02-25 2010-09-09 Kumamoto Univ アミロイド線維形成抑制剤及びその利用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5156965A (en) 1983-11-29 1992-10-20 Igen, Inc. Catalytic antibodies
CH668554A5 (de) 1984-04-09 1989-01-13 Sandoz Ag Liposomen welche polypeptide mit interleukin-2-aktivitaet enthalten sowie verfahren zu ihrer herstellung.
US4975282A (en) 1985-06-26 1990-12-04 The Liposome Company, Inc. Multilamellar liposomes having improved trapping efficiencies
DE3682257D1 (de) 1985-11-22 1991-12-05 Takeda Chemical Industries Ltd Liposomzusammensetzung.
JP2666345B2 (ja) 1987-04-16 1997-10-22 武田薬品工業株式会社 リポソーム製剤およびその製造法
US5273876A (en) 1987-06-26 1993-12-28 Syntro Corporation Recombinant human cytomegalovirus containing foreign gene
WO1990009441A1 (en) 1989-02-01 1990-08-23 The General Hospital Corporation Herpes simplex virus type i expression vector
US5665577A (en) 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
US5658753A (en) 1989-04-25 1997-08-19 Paul; Sudhir Catalytic antibody components
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
EP1285967A3 (en) 1990-09-21 2005-03-02 Chiron Corporation Human retroviral packaging cell line
DE69131908T3 (de) 1991-02-19 2008-04-03 Oxford Biomedica (Uk) Ltd. Viruspartikel mit veraendertem wirtspektrum
GB9105383D0 (en) 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
US5412087A (en) 1992-04-24 1995-05-02 Affymax Technologies N.V. Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
AU3972893A (en) 1992-04-03 1993-11-08 Baylor College Of Medicine Gene therapy using the intestine
WO1994012629A1 (en) 1992-12-02 1994-06-09 Baylor College Of Medicine Episomal vectors for gene therapy
EP0728202A4 (en) 1993-11-12 1997-04-23 Univ Case Western Reserve EPISOMIC EXPRESSION VECTOR FOR HUMAN GENE THERAPY
US5928944A (en) 1994-02-04 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method of adenoviral-medicated cell transfection
US5731172A (en) 1994-03-09 1998-03-24 Sumitomo Pharmaceuticals Company, Ltd. Recombinant adenovirus and process for producing the same
US5604090A (en) 1994-06-06 1997-02-18 Fred Hutchinson Cancer Research Center Method for increasing transduction of cells by adeno-associated virus vectors
US5693508A (en) 1994-11-08 1997-12-02 Chang; Lung-Ji Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats
JP3770333B2 (ja) 1995-03-15 2006-04-26 大日本住友製薬株式会社 組換えｄｎａウイルスおよびその製造方法
US6110456A (en) 1995-06-07 2000-08-29 Yale University Oral delivery or adeno-associated viral vectors
US5695937A (en) 1995-09-12 1997-12-09 The Johns Hopkins University School Of Medicine Method for serial analysis of gene expression
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
WO1997026919A2 (en) 1996-01-24 1997-07-31 Warner-Lambert Company Method of imaging amyloid deposits
US5861397A (en) 1996-10-03 1999-01-19 Vical Incorporated Piperazine based cytofectins
US6472436B1 (en) 2000-07-17 2002-10-29 The Salk Institute For Biological Studies Methods for protecting cells from amyloid toxicity and for inhibiting amyloid protein production
US7311893B2 (en) 2000-07-25 2007-12-25 Neurochem (International) Limited Amyloid targeting imaging agents and uses thereof
WO2002028441A2 (en) 2000-10-04 2002-04-11 California Institute Of Technology Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits
WO2002085903A2 (en) 2001-04-23 2002-10-31 The Trustees Of The University Of Pennsylvania Amyloid plaque aggregation inhibitors and diagnostic imaging agents
EP1414491A4 (en) 2001-07-09 2005-07-06 Elan Pharm Inc METHOD OF INHIBITING THE TOXICITY OF AMYLOID
US7250496B2 (en) 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
ATE405840T1 (de) 2002-12-19 2008-09-15 Scripps Research Inst Zusammensetzungen und verfahren zur stabilisierung von transthyretin und zur hemmung von transthyretin-fehlfaltung
ES2273202T3 (es) 2003-01-07 2007-05-01 Symphogen A/S Procedimiento para producir proteinas policlonales recombinantes.
US20060035946A1 (en) 2003-01-22 2006-02-16 The General Hospital Corporation Amyloid-binding, metal-chelating agents
GB0313386D0 (en) 2003-06-10 2003-07-16 Univ London Treatment of disease
US20060079578A1 (en) 2003-06-23 2006-04-13 Julie Laurin Pharmaceutical formulations of amyloid inhibiting compounds
TWI333977B (en) 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
US20050244869A1 (en) 2004-04-05 2005-11-03 Brown-Driver Vickie L Modulation of transthyretin expression
KR20070032700A (ko) 2004-05-20 2007-03-22 폴드알엑스 파마슈티칼스, 인크. 트랜스티레틴을 안정화하고 트랜스티레틴 미스폴딩을억제하기 위한, ２-((헤테로)아릴)-벤즈옥사졸 화합물 및유도체, 그리고 조성물 및 방법
ES2332524T3 (es) 2004-07-20 2010-02-08 Symphogen A/S Un procedimiento para la caracterizacion de una linea celular policlonal.
CA2638753A1 (en) 2004-12-08 2006-06-15 Sirion Therapeutics, Inc. Methods, assays and compositions for treating retinol-related diseases
US20070111258A1 (en) 2005-06-22 2007-05-17 Kaufman Randal J Compositions and methods for modulating the acute phase response
EP1921916A2 (en) 2005-08-11 2008-05-21 The Scripps Research Institute Genistein inhibition of transthyretin amyloidosis
US7700616B2 (en) 2006-05-08 2010-04-20 Molecular Neuroimaging, Llc. Compounds and amyloid probes thereof for therapeutic and imaging uses
CA2668640A1 (en) * 2006-11-01 2008-05-29 George Mason Intellectual Properties, Inc. Biomarkers for neurological conditions
WO2008141074A1 (en) 2007-05-10 2008-11-20 Salk Institute For Biological Studies Identification of compounds that protect against amyloid diseases
HRP20100640T1 (hr) 2007-05-25 2010-12-31 Symphogen A/S Postupak proizvodnje rekombinantnog poliklonskog proteina
US20090123373A1 (en) 2007-11-05 2009-05-14 Yanming Wang Amyloid-imaging agents
CA2702322A1 (en) 2007-11-22 2009-05-28 Symphogen A/S A method for characterization of a recombinant polyclonal protein
WO2010030203A1 (en) 2008-09-09 2010-03-18 Biocodex - Incubação De Empresas De Ciências Da Vida, S.A. Monoclonal antibody to human amyloidogenic and modified forms of transthyretin and its use in the detection and treatment of fap and pathologies presenting modified ttr
AU2009301580B2 (en) * 2008-10-06 2015-11-26 The University Of British Columbia Methods and systems for predicting misfolded protein epitopes
US8283460B2 (en) 2008-10-15 2012-10-09 Somagenics, Inc. Short hairpin RNAs for inhibition of gene expression
EA036772B1 (ru) 2008-10-20 2020-12-18 Элнилэм Фармасьютикалз, Инк. Композиции и способы для ингибирования экспрессии транстиретина
CA2749163A1 (en) 2009-01-14 2010-07-22 The Salk Institute For Biological Studies Methods for screening and compounds that protect against amyloid diseases
US9101643B2 (en) 2009-11-03 2015-08-11 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of transthyretin (TTR)
WO2011100396A2 (en) * 2010-02-10 2011-08-18 Trustees Of Boston University Serum clusterin levels in systemic amyloidosis featuring cardiomyopathy
EP3329924B1 (en) 2010-03-29 2021-05-05 Alnylam Pharmaceuticals, Inc. Dsrna therapy for transthyretin (ttr) related ocular amyloidosis
WO2011140333A1 (en) 2010-05-07 2011-11-10 The Board Of Trustees Of The Leland Stanford Junior University Identification of stabilizers of multimeric proteins
US9534048B2 (en) * 2012-08-24 2017-01-03 University Health Network Antibodies to TTR and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010195710A (ja) * 2009-02-25 2010-09-09 Kumamoto Univ アミロイド線維形成抑制剤及びその利用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PROC. NATL. ACAD. SCI. U S A., vol. 96, no. 6, JPN6017049921, 16 March 1999 (1999-03-16), pages 3108 - 3113, ISSN: 0003913330 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11912759B2 (en) 2015-01-28 2024-02-27 Novo Nordisk A/S Anti-transthyretin antibodies
JP2020536532A (ja) * 2017-10-06 2020-12-17 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
JP7357609B2 (ja) 2017-10-06 2023-10-06 ノボ ノルディスク エー／エス 抗トランスサイレチン抗体
US12247985B2 (en) 2017-10-06 2025-03-11 Novo Nordisk A/S Methods of detecting transthyretin
US11873332B2 (en) 2017-11-29 2024-01-16 Novo Nordisk A/S Lyophilized formulation of a monoclonal antibody against transthyretin
JP2020188700A (ja) * 2019-05-21 2020-11-26 国立大学法人 熊本大学 アミロイドーシス治療薬の新規スクリーニング方法及びアミロイドーシスのための医薬組成物
JP7360142B2 (ja) 2019-05-21 2023-10-12 国立大学法人 熊本大学 アミロイドーシス治療薬の新規スクリーニング方法

Also Published As

Publication number Publication date
EP2953970A4 (en) 2016-06-29
US20160039916A1 (en) 2016-02-11
WO2014124334A3 (en) 2014-12-24
US20180022797A1 (en) 2018-01-25
US9790269B2 (en) 2017-10-17
EP2953970A2 (en) 2015-12-16
WO2014124334A2 (en) 2014-08-14

Similar Documents

Publication Publication Date Title
US9790269B2 (en) Transthyretin antibodies and uses thereof
JP7244600B2 (ja) 過リン酸化タウに特異的な抗体およびその使用方法
JP6050124B2 (ja) Ｗｎｔシグナル伝達経路を阻害するモノクローナル抗体ならびにその製造方法およびその使用方法
JP5475994B2 (ja) 抗Ａβグロブロマー抗体、その抗原結合部分、対応するハイブリドーマ、核酸、ベクター、宿主細胞、前記抗体を作製する方法、前記抗体を含む組成物、前記抗体の使用及び前記抗体を使用する方法。
JP6345655B2 (ja) タウに対する抗体
Chukwu et al. Tau antibody structure reveals a molecular switch defining a pathological conformation of the tau protein
Kabayama et al. An ultra-stable cytoplasmic antibody engineered for in vivo applications
SG183854A1 (en) Oligomer-specific amyloid beta epitope and antibodies
JP2010530735A (ja) 細胞内のｐｒｌ−１ポリペプチドまたはｐｒｌ−３ポリペプチドに結合する抗体
TW201542589A (zh) 偵測人類ｐｅｒｉｏｓｔｉｎ之新穎分析法
JP5654989B2 (ja) グッドパスチャー抗原結合タンパク質およびその検出
JPWO2020032027A1 (ja) アルツハイマー病の判定薬および判定方法
US20220363738A1 (en) Method
JP2012507003A (ja) チトクロームｃアセチル化の検出及び調節
Zhang et al. Single chain variable fragment against Aβ expressed in baculovirus inhibits Abeta fibril elongation and promotes its disaggregation
WO2023208119A1 (zh) 作为早老性痴呆诊断标志物的ddit4l剪切产物
WO2023034324A2 (en) Methods and materials to treat neurodegenerative disease
US20140271463A1 (en) Bri2 as a novel biomarker for alzheimer's disease
JP5971966B2 (ja) Ｔｄｐ−４３の凝集体が蓄積する疾患の発症リスクを予測する方法、診断薬及び治療薬
US20240352102A1 (en) Compositions for treating tauopathies and methods of use thereof
Köppen et al. Identification of isoaspartate-modified transthyretin as potential target for selective immunotherapy of transthyretin amyloidosis
US20110027288A1 (en) Human monoclonal antibodies against amyloid beta protein, and their use as therapeutic agents
Class et al. Patent application title: BRI2 AS A NOVEL BIOMARKER FOR ALZHEIMER'S DISEASE Inventors: Marta Del Campo Milan (Amsterdam, NL) Cornelia Ramona Jimenez (Amsterdam, NL) Chrlott Elisabeth Teunissen (Amsterdam, NL) Assignees: Stichting VU-VUmc
JP2024009473A (ja) 筋炎／皮膚筋炎やそれに併発する間質性肺炎を発症するモデル動物
Galant Therapeutic Monoclonal Antibodies to Detect and Halt ATTR Cardiac Amyloidosis and Neuropathy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170124

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20171129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180327

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180622

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181105